Biotech Conferences Week 2 Day 2 Part 1 - Connect Biopharma Holdings Limited

CNTB (quick overview): At $1.14, Connect Biopharma is a high-upside but lower-visibility regulatory-development story centered on rademikibart’s potential to create an acute respiratory-care category. Phase 2 missed statistical significance on treatment failure despite a 66% relative reduction, but delivered statistically significant FEV1 improvement by Day 7, with management describing benefit from Day 3 through Day 28. A late-2026 FDA meeting is pivotal: agreement on an FEV1-based path could enable Phase 3 in early 2027, while different requirements could complicate development.

Read full article (2 min)